CN1053108C - Chinese patent medicine for treating primary liver cancer - Google Patents
Chinese patent medicine for treating primary liver cancer Download PDFInfo
- Publication number
- CN1053108C CN1053108C CN94105640A CN94105640A CN1053108C CN 1053108 C CN1053108 C CN 1053108C CN 94105640 A CN94105640 A CN 94105640A CN 94105640 A CN94105640 A CN 94105640A CN 1053108 C CN1053108 C CN 1053108C
- Authority
- CN
- China
- Prior art keywords
- patent medicine
- radix
- liver cancer
- chinese patent
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 201000007270 liver cancer Diseases 0.000 title abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 23
- 241000218176 Corydalis Species 0.000 claims abstract description 10
- 241000237903 Hirudo Species 0.000 claims description 10
- 244000293323 Cosmos caudatus Species 0.000 claims description 9
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 9
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 208000014018 liver neoplasm Diseases 0.000 abstract description 15
- 230000004083 survival effect Effects 0.000 abstract description 10
- 210000000952 spleen Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 241000282817 Bovidae Species 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 244000272264 Saussurea lappa Species 0.000 abstract 1
- 235000006784 Saussurea lappa Nutrition 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000000463 material Substances 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241001489978 Eupolyphaga Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese patent medicine for treating primary liver cancer, the effective rate of the same Chinese patent medicine for treating liver cancer at home at present is generally below 60%, the invention adopts costus root, salvia miltiorrhiza, rhizoma corydalis, bezoar, radix curcumae, antelope horn powder, pearl powder, musk, leech and other Chinese herbal medicines to prepare oral patent medicines according to the treatment principle of soothing liver, resolving stagnation, softening hardness, dissipating stagnation, reducing swelling, relieving pain, strengthening spleen and replenishing qi, the effective rate for treating primary late-stage liver cancer can reach 83.7%, the survival rate of more than five years reaches 22.5%, and the Chinese patent medicine has quick effect and small toxic and side effects.
Description
The invention belongs to a kind of Chinese patent medicine for the treatment of primary hepatocarcinoma.
China dies from the philtrum of malignant tumor every year, liver cancer patient accounts for 15%, and onset of liver cancer is many with person between twenty and fifty, and this disease PD is rapid, prognosis mala, be acknowledged as one of difficult treatment kind, doctor trained in Western medicine is main means to liver cancer treatment with radiotherapy, chemotherapy and operation, according to " second the Shanghai radiation oncology meeting " of in April, 91 in held in Hangzhou, Shanghai adopts full liver to move the bar radiation, merge Chinese traditional treatment, five year survival rate is 3.8%, and thinks and reach higher level.Other has report, has liver cancer patient more than half to adopt the Chinese herbal medicine therapy approximately." practical internal medicine " (86 years people's democracy publishing houses) and outstanding " traditional Chinese medical science oncology " (the 83 years Science Presses) of Yu Rencun according to Shanghai Medical Univ's work: the annual rate about 30% of depositing of present domestic Chinese medicine liver cancer patient.Its main method is early stage many based on the soothing the liver spleen of building, then be basic principle late period with the replenishing YIN and removing heat, for example go up publication Wang Ze light etc. with ruling by law such as dispersing the stagnated live-QI to relieve the stagnation of QI, blood circulation promoting and blood stasis dispelling, Replenishing QI and nourishing YIN treat 110 routine primary hepatocarcinoma, effective percentage 59% preferably by 90 years the 5th phases " Beijing traditional Chinese medical science " for curative effect; 90 year first phase " gradually river college of traditional Chinese medicine journal " report Chen You orchid is to 106 routine advanced liver cancers dispersing the stagnated live-QI to relieve the stagnation of QI methods, removing pathogenic heat from blood and toxic substance from the body method and movable blood soft hard method etc., survival rate 55.3% in three months, 6 months is 18.5%, the human spleen invigorating sides of regulating the flow of vital energy such as " combination of Chinese and Western medicine magazine " 90 years the tenth second phases report Hu Bin add Western medicine Ah toxin, treatment hepatocarcinoma 16 examples, remission rate 31.1%, 12.6 months mean survival time (MST)s; Tumour hospital of Shanghai Medical Univ is in your hot 90 years reports, the annual rate 20.83% of depositing behind the III phase liver cancer treatment, survival rate 6.94 ± 5.93% in 3 years, median survival interval only 7.5 months, in a word, Chinese traditional treatment advanced liver cancer curative effect is still not satisfied at present, and average survival period still is about 8 months to 1 year.
The present invention aims to provide a kind of curative effect height, instant effect, improves the oral Chinese patent medicine of the treatment primary hepatocarcinoma that symptom is definite, toxic and side effects is little.
For achieving the above object, Chinese patent medicine of the present invention adopts following material composition and weight proportion to make:
Radix Aucklandiae (Radix Vladimiriae) 10～15b Radix Salviae Miltiorrhizae 15～20b Rhizoma Corydalis 15～20b
Radix Curcumae 15～20b Cornu Saigae Tataricae powder 6～10b Margarita powder～10b
Natural Calculus Bovis 1～6b Hirudo 1～5b Moschus 1～6b
Wherein b is a Unit Weight part;
Above-mentioned raw materials is made the oral Chinese patent medicine of various dosage forms with conventional concocting method.
Hepatocarcinoma is to cause a disease because of multiple factor, advanced liver cancer patient particularly, " gas ", " fire ", " poison ", it is the main cause of morbidity, patient's body constitution then shows as weakness of the spleen and stomach, so stagnation of QI due to depression of the liver, the QI and blood stasis of blood is closed, send out to disease and amass, strongly fragrant fire-transformation of a specified duration, injure taste, fortuneization mistake department, so the present invention adopts soothing liver-QIization strongly fragrant, hard masses softening and resolving, reducing swelling and alleviating pain, invigorating the spleen and benefiting QI, the removing heat from blood dampness removing is main treatment rule, caught the principal contradiction of hepatocarcinoma, consider " gas " in addition, " fire ", " poison " three is not independently, but interknit, " gas ", be the blood general, the liver cancer patient often deficiency of vital energy causes blood deficiency, though the part shows with " reality ", but be deficiency in origin and excess in superficiality, pathogenic fire derived from stagnation of liver-QI is the symptom of dampness-heat in the liver and gallbladder, " poison " means qi depression to blood stasis, depressed emotion, phlegm-damp stagnates and gathering of forming, thus this therapy from patient's integral body, treating both the principal and secondary aspects of a disease.
Calculus Bovis is the main Chinese medicine of heat-clearing and toxic substances removing, eliminating stagnation blood stasis removing in the side; convulsion is arranged and suppress the tumor cell effect; Radix Salviae Miltiorrhizae, Radix Curcumae, Hirudo, Rhizoma Corydalis are used; can strengthen the promoting blood circulation and detumescence effect; Radix Aucklandiae (Radix Vladimiriae) has the invigorating the spleen and benefiting QI effect, can promote the carcinoma eliminating stagnation, and Cornu Saigae Tataricae powder is the principal agent of suppressing the hyperactive liver to relieve the wind syndrome;, detumescence pathogenic fire reducing flourishing to liver-fire has siddhi, but Moschus, Margarita powder heat-clearing and toxic substances removing, detumescence dissipating blood stasis.Said medicine is worked in coordination, and can play that the heat clearing away that uncharms, eliminating stagnation are active, alleviating pain and detumescence, the strongly fragrant effect of soothing liver-QIization, to " gas ", " fire ", " poison " antagonism targetedly of hepatocarcinoma.
This Chinese patent medicine is used for 80 examples makes a definite diagnosis through various big hospitals, integrative therapy is invalid and be judged to the patient of late primary liver cancer, and its clinical test results is as follows: produce effects: 26 examples (32.5%); Improve: 41 examples (51.2%); Invalid: 13 examples (16.3%); Total effective rate is 83.7%.
The criterion of above-mentioned curative effect is:
Produce effects-treatment back pain disappears, and abdominal mass disappears, and jaundice disappears, and it is normal that hepatosplenomegaly portion recovers.
Improve-with after this law treatment, pain control, hepatic region lump dwindle, big disappearance of ascites, and clinical symptoms makes moderate progress.
After invalid-treatment three courses of treatment, various cardinal symptoms do not have obvious improvement, or the state of an illness increases the weight of.
After the treatment, the 80 routine advanced liver cancer patients situation of surviving is as shown in the table:
1 year 2 years 3 years 4 years 69 47 29 22 18 death tolls, 11 22 18 74 survival rates of survival number more than 5 years (%) 86.2 58.7 36.2 27.5 22.5
Wherein, 5 routine advanced liver cancer patients have been survived more than 8 years so far.
The conclusion of this medicine being carried out toxicity test is:
1, rat is the 500g/kg body weight to the maximum tolerated dose of medical herbs extractum, belongs to nontoxic medical herbs.
2, medical herbs extractum is to the influence of rat paddy transaminase (GPT) vigor, blood urea nitrogen, Hb, RBC counting: with matched group relatively there are no significant difference (p＞0.05).
3, negative to the mouse microkernel test result.
This Chinese patent drugs for treatment constitutional advanced liver cancer toxic and side effects is little, and it is rapid to improve symptom, the curative effect height, and through 80 routine patient's clinical trials statistics, total effective rate reaches that survival rate reaches 22.5% more than 83.7%, five year, evident in efficacyly is higher than domestic similar Drug therapy level.
The embodiment explanation:
Embodiment one, and this routine patent medicine adopts following base stock and proportioning to make, and wherein b represents a Unit Weight part:
Radix Aucklandiae (Radix Vladimiriae) 13b Radix Salviae Miltiorrhizae 18b Rhizoma Corydalis 18b
Radix Curcumae 18b Cornu Saigae Tataricae powder 8b Margarita powder 8b
Natural Calculus Bovis 4b Hirudo 3b Moschus 4b
Get material by the above-mentioned raw materials proportioning and make pill patent medicine.
Embodiment two, and this routine patent medicine adopts following base stock and proportioning for every dose:
Radix Aucklandiae (Radix Vladimiriae) 10g Radix Salviae Miltiorrhizae 15g Rhizoma Corydalis 15g
Radix Curcumae 15g Cornu Saigae Tataricae powder 6g Margarita powder g
Natural Calculus Bovis 1g Hirudo 1g Moschus 1g
Get material by the above-mentioned raw materials proportioning and make tablet patent medicine, took 3 days every day 2～3 times for every dose.
Embodiment three, and this routine patent medicine adopts following base stock and proportioning for every dose:
Radix Aucklandiae (Radix Vladimiriae) 15g Radix Salviae Miltiorrhizae 20g Rhizoma Corydalis 20g
Radix Curcumae 20g Cornu Saigae Tataricae powder 10g Margarita powder 10g
Natural Calculus Bovis 6g Hirudo 5g Moschus 6g
Get material by the above-mentioned raw materials proportioning and make patent medicine, took 3 days every day 2～3 times for every dose.
Embodiment four, and this routine patent medicine adopts following base stock and proportioning for every dose:
Radix Aucklandiae (Radix Vladimiriae) 12g Radix Salviae Miltiorrhizae 17g Rhizoma Corydalis 17g
Radix Curcumae 17g Cornu Saigae Tataricae powder 7 g Margarita powder g
Natural Calculus Bovis 3g Hirudo 3g Moschus 8g
Radix Et Rhizoma Rhei 6g Fructus Amomi 18g Fructus Polygoni Orientalis 18g
Eupolyphaga 3g Herba Sedi 18g Herba Scutellariae Barbatae 28g
Radix Et Rhizoma Rhei, Herba Scutellariae Barbatae, Herba Sedi are heat and toxic materials clearing away medicine in the side, and Hirudo, eupolyphaga can strengthen the promoting blood circulation and detumescence effect, Fructus Amomi, Fructus Polygoni Orientalis invigorating the spleen and benefiting QI, and drug effect can be further strengthened in the adding of these medicines, and the weight range of getting that these a few flavor medicines are every dose is:
Radix Et Rhizoma Rhei 5～7g Fructus Amomi 15～20g Fructus Polygoni Orientalis 15～20g
Eupolyphaga 1～5g Herba Sedi 15～20g Herba Scutellariae Barbatae 25～30g
The capsular processing technology of this routine patent medicine is:
1, gets material by above-mentioned prescription, Radix Aucklandiae (Radix Vladimiriae), Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei, Fructus Amomi, Rhizoma Corydalis, Fructus Polygoni Orientalis, Hirudo, eupolyphaga, Radix Curcumae, Herba Sedi, Herba Scutellariae Barbatae are added water logging be not degree, decoct three times, decoction liquor is concentrated, make every milliliter of concentrated solution contain crude drug 1g with membrane evaporator.
2, with ethanol with medicinal liquid sedimentation, filtration, once more filtrate is concentrated with membrane evaporator, make every milliliter of medicinal liquid contain crude drug 4～5g, put into vacuum drying oven then and be heated to 62 ℃, be dried to graininess.
3, with Calculus Bovis, Moschus, Cornu Saigae Tataricae powder, Margarita powder porphyrize, admix in the above-mentioned concentrated medicated powder of making, mix thoroughly, make brown Chinese medicinal powder.
With the medicated powder capsule of packing into No. 3.
Consumption: each oral 3, every day 3 times.
Claims (2)
1, the Chinese patent medicine of treatment primary hepatocarcinoma, it is characterized in that: raw material and weight proportion that described patent medicine adopts are:
Radix Aucklandiae (Radix Vladimiriae) 10～15b Radix Salviae Miltiorrhizae 15～20b Rhizoma Corydalis 15～20b
Radix Curcumae 15～20b Cornu Saigae Tataricae powder 6～10b Margarita powder 6～10b
Natural Calculus Bovis 1～6b Hirudo 1～5b Moschus 1～6b
Wherein b is a Unit Weight part;
Above-mentioned raw materials is made the oral patent medicine of various dosage forms.
2, Chinese patent medicine as claimed in claim 1 is characterized in that: the base stock and the weight proportion of every dose of use of described patent medicine are:
Radix Aucklandiae (Radix Vladimiriae) 13g Radix Salviae Miltiorrhizae 18g Rhizoma Corydalis 18g
Radix Curcumae 18g Cornu Saigae Tataricae powder 8g Margarita powder 8g
Natural Calculus Bovis 3g Hirudo 3g Moschus 3g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94105640A CN1053108C (en) | 1994-05-24 | 1994-05-24 | Chinese patent medicine for treating primary liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94105640A CN1053108C (en) | 1994-05-24 | 1994-05-24 | Chinese patent medicine for treating primary liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1098937A CN1098937A (en) | 1995-02-22 |
| CN1053108C true CN1053108C (en) | 2000-06-07 |
Family
ID=5032121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94105640A Expired - Fee Related CN1053108C (en) | 1994-05-24 | 1994-05-24 | Chinese patent medicine for treating primary liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1053108C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107468949B (en) * | 2017-09-30 | 2020-10-30 | 广西壮族自治区肿瘤防治研究所 | Traditional Chinese medicine composition for treating advanced primary liver cancer and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1038212A (en) * | 1988-06-03 | 1989-12-27 | 谢邦和 | The preparation method of " Ai-Ning " (caner meprobamate) injection |
| CN1058911A (en) * | 1990-08-05 | 1992-02-26 | 陈江辉 | The compound method of capsule for curing tumour |
-
1994
- 1994-05-24 CN CN94105640A patent/CN1053108C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1038212A (en) * | 1988-06-03 | 1989-12-27 | 谢邦和 | The preparation method of " Ai-Ning " (caner meprobamate) injection |
| CN1058911A (en) * | 1990-08-05 | 1992-02-26 | 陈江辉 | The compound method of capsule for curing tumour |
Non-Patent Citations (3)
| Title |
|---|
| 广东医学1984,5(11) 1984.11.30 张荣等，莲花片治疗原发性肝癌61例临床观察 * |
| 广东医学1984,5(11) 1984.11.30 张荣等，莲花片治疗原发性肝癌61例临床观察;新药与临床1984,3(2) 1984.2.29 陈雪良，葫芦素治疗原发性肝癌50例临床观察 * |
| 新药与临床1984,3(2) 1984.2.29 陈雪良，葫芦素治疗原发性肝癌50例临床观察 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1098937A (en) | 1995-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1374880B1 (en) | An antineoplastic drug | |
| CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
| CN1305515C (en) | Chinese medicinal powder and decoction composition for treating cancer | |
| CN102078569A (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN101711848A (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1053108C (en) | Chinese patent medicine for treating primary liver cancer | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1071123C (en) | Preparatory Chinese-medicine for treatment of hepatitis and hepatoascites | |
| CN101612205B (en) | Traditional Chinese medicine for treating ulcerative colitis | |
| CN112717097A (en) | Traditional Chinese medicine composition for treating gastric cancer and preparation method thereof | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN100488526C (en) | Oral preparation | |
| CN1074292C (en) | Cancer treating medicine capsule | |
| CN1876148A (en) | A Chinese medicinal composition for replenishing kidney and strengthening bone and preparation method thereof | |
| CN111012865A (en) | Application of kidney-tonifying brain-benefiting preparation in preparation of medicine for treating tumors | |
| CN110538280A (en) | antidepressant confirmed by pharmacological activity and preparation method thereof | |
| CN101721610B (en) | Medicine for treating tumors | |
| CN100473403C (en) | Anti-cancer capsules | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method | |
| CN100348260C (en) | Method for treating throat cancer | |
| CN1253003A (en) | Compound graceful jassamine preparation | |
| CN110960664A (en) | Traditional Chinese medicine composition for treating cancer and preparation method and application thereof | |
| CN112107656A (en) | Anticancer Chinese medicinal preparation and its preparation method | |
| CN1205987C (en) | Medicine for treating cirrhosis | |
| CN115252679A (en) | Traditional Chinese medicine composition for treating ischemic cardiomyopathy and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |